MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Pfizer
Pfizer
Merck Sharp & Dohme LLC
Pfizer
Merck Sharp & Dohme LLC
Canadian Cancer Trials Group
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
National Cancer Institute (NCI)
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Regeneron Pharmaceuticals
Alliance for Clinical Trials in Oncology
Alexion Pharmaceuticals, Inc.
Eastern Cooperative Oncology Group
Eastern Cooperative Oncology Group
Celgene
University Hospital, Caen
Merck Sharp & Dohme LLC
Intergroupe Francophone du Myelome
Bristol-Myers Squibb
Children's Oncology Group
Children's Oncology Group
GlaxoSmithKline
Pfizer
Gilead Sciences
European Myeloma Network B.V.
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Celgene
Children's Cancer Group, China
Alexion Pharmaceuticals, Inc.
European Myeloma Network B.V.
AbbVie
Janssen Research & Development, LLC
AstraZeneca
Regeneron Pharmaceuticals
University of Chicago
University of Chicago
Affiliated Hospital of Guangdong Medical University
Heron Therapeutics
Qilu Pharmaceutical Co., Ltd.
The Netherlands Cancer Institute
Children's Oncology Group
University of Heidelberg Medical Center
The Affiliated People's Hospital of Ningbo University